102 related articles for article (PubMed ID: 10706080)
1. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy.
Capparelli C; Kostenuik PJ; Morony S; Starnes C; Weimann B; Van G; Scully S; Qi M; Lacey DL; Dunstan CR
Cancer Res; 2000 Feb; 60(4):783-7. PubMed ID: 10706080
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo.
Uy HL; Mundy GR; Boyce BF; Story BM; Dunstan CR; Yin JJ; Roodman GD; Guise TA
Cancer Res; 1997 Aug; 57(15):3194-9. PubMed ID: 9242449
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.
Oyajobi BO; Anderson DM; Traianedes K; Williams PJ; Yoneda T; Mundy GR
Cancer Res; 2001 Mar; 61(6):2572-8. PubMed ID: 11289133
[TBL] [Abstract][Full Text] [Related]
4. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.
Fisher JL; Thomas-Mudge RJ; Elliott J; Hards DK; Sims NA; Slavin J; Martin TJ; Gillespie MT
Cancer Res; 2006 Apr; 66(7):3620-8. PubMed ID: 16585187
[TBL] [Abstract][Full Text] [Related]
5. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.
Morony S; Warmington K; Adamu S; Asuncion F; Geng Z; Grisanti M; Tan HL; Capparelli C; Starnes C; Weimann B; Dunstan CR; Kostenuik PJ
Endocrinology; 2005 Aug; 146(8):3235-43. PubMed ID: 15845617
[TBL] [Abstract][Full Text] [Related]
6. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.
Morony S; Capparelli C; Sarosi I; Lacey DL; Dunstan CR; Kostenuik PJ
Cancer Res; 2001 Jun; 61(11):4432-6. PubMed ID: 11389072
[TBL] [Abstract][Full Text] [Related]
7. Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption.
Onyia JE; Galvin RJ; Ma YL; Halladay DL; Miles RR; Yang X; Fuson T; Cain RL; Zeng QQ; Chandrasekhar S; Emkey R; Xu Y; Thirunavukkarasu K; Bryant HU; Martin TJ
J Pharmacol Exp Ther; 2004 Apr; 309(1):369-79. PubMed ID: 14718597
[TBL] [Abstract][Full Text] [Related]
8. Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice.
Clohisy DR; Ramnaraine ML; Scully S; Qi M; Van G; Tan HL; Lacey DL
J Orthop Res; 2000 Nov; 18(6):967-76. PubMed ID: 11192258
[TBL] [Abstract][Full Text] [Related]
9. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
[TBL] [Abstract][Full Text] [Related]
10. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3.
Morony S; Capparelli C; Lee R; Shimamoto G; Boone T; Lacey DL; Dunstan CR
J Bone Miner Res; 1999 Sep; 14(9):1478-85. PubMed ID: 10469275
[TBL] [Abstract][Full Text] [Related]
11. Effects of anti-parathyroid hormone-related protein monoclonal antibody and osteoprotegerin on PTHrP-producing tumor-induced cachexia in nude mice.
Iguchi H; Aramaki Y; Maruta S; Takiguchi S
J Bone Miner Metab; 2006; 24(1):16-9. PubMed ID: 16369893
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-4 inhibits spontaneous and parathyroid hormone-related protein-stimulated osteoclast formation in mice.
Nakano Y; Watanabe K; Morimoto I; Okada Y; Ura K; Sato K; Kasono K; Nakamura T; Eto S
J Bone Miner Res; 1994 Oct; 9(10):1533-9. PubMed ID: 7817798
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice.
Tabuchi M; Miyazawa K; Kimura M; Maeda H; Kawai T; Kameyama Y; Goto S
Calcif Tissue Int; 2005 Oct; 77(4):239-49. PubMed ID: 16193235
[TBL] [Abstract][Full Text] [Related]
14. Magnesium deficiency: effect on bone and mineral metabolism in the mouse.
Rude RK; Gruber HE; Wei LY; Frausto A; Mills BG
Calcif Tissue Int; 2003 Jan; 72(1):32-41. PubMed ID: 12370796
[TBL] [Abstract][Full Text] [Related]
15. Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model.
Yang SY; Mayton L; Wu B; Goater JJ; Schwarz EM; Wooley PH
Arthritis Rheum; 2002 Sep; 46(9):2514-23. PubMed ID: 12355500
[TBL] [Abstract][Full Text] [Related]
16. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
Sordillo EM; Pearse RN
Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
[TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.
Schett G; Redlich K; Hayer S; Zwerina J; Bolon B; Dunstan C; Görtz B; Schulz A; Bergmeister H; Kollias G; Steiner G; Smolen JS
Arthritis Rheum; 2003 Jul; 48(7):2042-51. PubMed ID: 12847699
[TBL] [Abstract][Full Text] [Related]
18. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K
J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054
[TBL] [Abstract][Full Text] [Related]
19. Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice.
Cui N; Nomura T; Noma H; Yokoo K; Takagi R; Hashimoto S; Okamoto M; Sato M; Yu G; Guo C; Shibahala T
Clin Cancer Res; 2005 Apr; 11(7):2713-9. PubMed ID: 15814653
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of malignancy-associated hypercalcemia].
Endo I; Inoue D
Clin Calcium; 2006 Apr; 16(4):665-69. PubMed ID: 16582519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]